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E3 ubiquitin ligase Cbl-b has emerged as a gate-
keeper that controls the activation threshold of the
T cell antigen receptor andmaintains the balance be-
tween tolerance and autoimmunity. Here, we report
that the loss of Cbl-b facilitates T helper 2 (Th2) and
Th9 cell differentiation in vitro. In a mouse model of
asthma, the absence of Cbl-b results in severe airway
inflammation and stronger Th2 and Th9 responses.
Mechanistically, Cbl-b selectively associates with
Stat6 upon IL-4 ligation and targets Stat6 for ubi-
quitination and degradation. These processes are
heightened in the presence of T cell receptor (TCR)/
CD28 costimulation. Furthermore, we identify K108
and K398 as Stat6 ubiquitination sites. Intriguingly,
introducing Stat6 deficiency into Cblb/mice abro-
gates hyper-Th2 responses but only partially attenu-
ates Th9 responses. Therefore, our data reveal a
function for Cbl-b in the regulation of Th2 and Th9
cell differentiation.INTRODUCTION
Antigenic stimulation of T cells drives naive CD4 T helper (Th)
cells into functionally distinct subsets of Th cells that are depen-Cdent upon many factors, including the affinity of T cell receptor
(TCR) for antigen, the concentration of antigen during TCR trig-
gering, and in particular the cytokine milieu (Murphy et al.,
2000). Th1 cells are characterized by the production of proin-
flammatory interferon g (IFN-g) to mediate cellular immunity,
whereas Th2 cells produce interleukin-4 (IL-4), IL-5, and IL-13,
and are responsible for regulating humoral immunity and, in
pathological conditions, asthma and allergy. Recently, newly
identified Th17 cells, distinct from Th1 and Th2 cells, were
shown to produce IL-17, IL-17F, IL-22, and IL-21, and mediate
tissue inflammation (Harrington et al., 2006; Park et al., 2005).
In addition to Th1, Th2, and Th17, a recently identified Th subset
specialized for the production of IL-9, termed Th9, was shown to
be generated in the presence of transforming growth factor b
(TGF-b) and IL-4 (Dardalhon et al., 2008; Veldhoen et al.,
2008). Th9 cells are related to Th2 cells in that they require signal
transducer and activator of transcription 6 (Stat6), GATA-binding
protein 3 (GATA3), and interferon-regulatory factor 4 (IRF4) for
development but are distinct from Th2 cells in their requirement
for PU.1 (Chang et al., 2010; Kaplan, 2013; Staudt et al., 2010).
Th9 cells have also been shown to contribute to allergic inflam-
mation (Chang et al., 2010; Kaplan, 2013; Yao et al., 2013).
IL-4 is the determining factor for Th2 cell differentiation. In this
regard, IL-4 is a key cytokine in the development of allergic
inflammation (Chatila, 2004). Binding of IL-4 to the IL-4 receptor
(IL-4R) triggers phosphorylation of Janus kinase-1 (JAK-1) and
JAK-3, leading to the activation of Stat6. Tyrosine-phosphory-
lated Stat6 forms homodimers and translocates into the nucleus,ell Reports 6, 709–723, February 27, 2014 ª2014 The Authors 709
where it binds IL-4-responsive elements (Takeda et al., 1996;
Wurster et al., 2000), which, together with NF-AT, AP-1, NF-
kB, and other TCR-induced signal mediators, activates the
transcription of IL-4 as well as the transcription factor GATA3,
a signature mediator of Th2 lineage commitment. Stat6 has
also been documented to be critical for induction of Th9 cell
differentiation (Goswami et al., 2012). However, the molecular
basis of how the signals derived from TCR and IL-4R can be
integrated has yet to be defined.
Cbl-b is an E3 ubiquitin ligase that contains multiple do-
mains, including a protein tyrosine kinase-binding (TKB)
domain, a RING-finger (RF) domain, and a proline-rich region.
The RF domain is the site in which Cbl family proteins recruit
ubiquitin-conjugating enzymes, which add ubiquitin to targeted
proteins. The TKB domain has been shown to recognize spe-
cific phosphotyrosine residues on target proteins for ubiquitin
conjugation (Thien and Langdon, 2005). These domains are
required for Cbl proteins to regulate cell signaling and protein
degradation. Gene targeting in mice has indicated that Cbl-b
is a gatekeeper that maintains a balance between immunity
and tolerance. Indeed, signaling via CD28 and CTLA-4 tightly
regulates Cbl-b expression (Zhang et al., 2002; Li et al.,
2004), which is critical for establishing the threshold for T cell
activation and tolerance. In strong support of this notion,
Cblb/ T cells are resistant to anergy induction in vitro and
in vivo (Heissmeyer et al., 2004; Jeon et al., 2004). However,
whether Cbl-b also plays a role in Th cell differentiation remains
to be elucidated.
In this study, we report that loss of Cbl-b leads to a skewed
Th2 and Th9 phenotype, which results in augmented airway
inflammation. Upon IL-4 stimulation, Cbl-b specifically associ-
ates with Stat6, targeting it for ubiquitination and degradation,
a process that is further heightened by TCR signaling. Surpris-
ingly, Stat6 deficiency abrogates hyper-Th2 responses but only
partially attenuates Th9 responses in Cblb/ mice. This sug-
gests that Cbl-b regulates Th2 cell differentiation via a Stat6-
dependent mechanism but regulates Th9 cell differentiation
via both Stat6-dependent and -independent mechanisms.
RESULTS
Cbl-b Negatively Regulates Th2 and Th9 Cell
Differentiation In Vitro
To assess whether Cbl-b affects Th cell differentiation, we
measured the expression of Cbl-b protein in differentiated Th1,
Th2, and Th17 cells by intracellular staining. Although the
expression of Cbl-b was increased in Th1, Th2, and Th17 cells,
as determined by the mean fluorescence intensity (MFI) of
Cbl-b, its expression was significantly lower in Th2 cells than in
Th1 and Th17 cells, suggesting that Cbl-b may play a role in
Th2 cell differentiation (Figure S1A). The increase in Cbl-b protein
expression upon chronic TCR stimulation is consistent with our
previous report (Li et al., 2004). To confirm this further, we
assessed the expression of Cbl-b in differentiating Th1, Th2,
Th9, and Th17 cells by intracellular staining. Cbl-b expression
was markedly lower in Th9 and Th2 cells than in Th1 and Th17
cells during the differentiation process, with the lowest levels
occurring in Th9 cells (Figure S1B).710 Cell Reports 6, 709–723, February 27, 2014 ª2014 The AuthorsTo determine the potential role of Cbl-b in Th cell differentia-
tion, we examined the cytokine profile of naive CD4+ T cells
from wild-type (WT) and Cblb/mice upon CD3/CD28 stimula-
tion. Although WT and Cblb/ T cells produced comparable
levels of IFN-g and IL-17, production of IL-4, IL-5, IL-9, and
IL-13 was significantly higher in Cblb/ T cells than in WT
T cells (Figure 1A). The increased production of IL-4, IL-5, IL-9,
and IL-13 by Cblb/ T cells supports the notion that Cbl-b
may inhibit Th2 and Th9 cytokine production.
To further analyze a possible functional role for Cbl-b in Th2
and Th9 cell differentiation, we performed in vitro Th1, Th2,
Th9, and Th17 differentiation assays. We observed an
augmented generation of IL-4+ Th2 cells and IL-9+ Th9 cells
derived from naive Cblb/ CD4+ T cells in comparison to those
derived from naive WT CD4+ T cells (Figure 1B). However, when
cells were cultured under Th1 and Th17 polarizing conditions,
no difference was observed in the generation of IFN-g+ Th1
cells or IL-17+ Th17 cells from WT and Cblb/ T cells (Figures
1B and 1C). To further confirm this observation using homo-
geneous populations of naive CD4+ T cells, we generated
DO11.10.Cblb+/+ and DO11.10.Cblb/ mice in which the I-Ad-
restricted DO11.10 TCR transgene is specific for a peptide
from chicken ovalbumin (OVA; aa 323–339, OVAp323-339) (Mur-
phy et al., 1990). Consistent with the data shown in Figure 1B,
loss of Cbl-b led to biased Th2 and Th9 cell differentiation of
DO11.10 T cells (Figure 1D).
Cblb/ Mice Are Highly Susceptible to Asthma
Induction and Display Heightened Th2 and Th9
Responses
To determine whether Cbl-b regulates Th2 and Th9 responses
in vivo, we used a mouse model of allergic asthma, which has
been shown to be mediated by both Th2 and Th9 cytokines
(Kaplan, 2013). As shown in Figure 2A, after immunization
and challenge with OVA, Cblb/ mice displayed more severe
inflammatory cell infiltration in the perivascular and peribron-
chial areas, goblet cell metaplasia, and increased mucus pro-
duction, as determined by hematoxylin and eosin (H&E) and
periodic acid-Schiff (PAS) staining of lung sections. As ex-
pected, Cblb/ mice had significantly more infiltrating cells
and eosinophils in bronchoalveolar lavage (BAL) fluid than WT
mice (Figure 2B).
Airway hyperresponsiveness (AHR) is a hallmark of asthma
and is often associated with increased airway inflammation
(Pernis and Rothman, 2002). To investigate whether the severe
airway inflammation in Cblb/ mice also leads to heightened
AHR, we measured respiratory system resistance (Rsr) changes
in response to methacholine (MetCh) aerosol at 24 hr after the
final dose of OVA challenge as described previously (Myou
et al., 2003). We found that Cblb/ mice remained hyperre-
sponsive to MetCh (Figure 2C). Cytokine analysis showed that
Cbl-b/ mice had significantly higher levels of IL-4, IL-5, IL-
13, and IL-9 in BAL fluid compared with WT mice, which closely
correlated with serum immunoglobulin E (IgE) production (Fig-
ure 2D). Note that the IFN-g level in the BAL of Cblb/ mice
was comparable to that of WT mice (Figure 2D). These data
indicate that the loss of Cbl-b specifically inhibits Th2 and Th9
responses in vivo.
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Figure 1. Loss of Cbl-b Favors Th2 and Th9 Cell Differentiation In Vitro
(A) ELISA results for cytokine production of purified naive CD4+CD25CD62LhiCD44lo T cells from WT or Cblb/ mice upon stimulation with plate-bound anti-
CD3 plus anti-CD28 for 48 hr (*p < 0.05, compared with Cblb/ mice).
(B andC) Intracellular staining of Th1, Th2, Th9, and Th17 cells differentiated in vitro from purified naive CD4+CD25CD62LhiCD44lo T cells ofWT orCblb/mice.
Numbers in the quadrants in (B) indicate the percentage of IL-4/IFN-g-producing cells in the CD4+ population. Numbers in the quadrants in (C) indicate the
percentage of IL-17/IL-9-producing cells in the CD4+ population.
(D) Intracellular staining of Th2 cells and Th9 cells differentiated in vitro from DO11.10 and DO11.10.Cblb/ naive CD4+ cells. Numbers in the quadrants indicate
the percentage of IL-4- and IL-9-producing cells. Data are representative of three independent experiments.As Cbl-b deficiency has been shown to affect B cells, mono-
cytes, and mast cells (Bachmaier et al., 2007; Qiao et al., 2007;
Gustin et al., 2006), whichmay potentially affect Th2 cell differen-
tiation, we investigated whether T cell-intrinsic loss of Cbl-b
results in heightened airway inflammation and aberrant Th2 re-
sponses. We therefore analyzed BALB/c nude mice that were
reconstituted with WT or Cblb/ naive CD4+CD25 T cells. As
shown in Figure 2E, BALB/c nude mice that received naiveCCblb/CD4+ T cells displayedmore severe airway inflammation
as well as heightened IL-4, IL-5, IL-9, and IL-13 in the BAL fluid,
and IgE in the serum, than those that received naive WT CD4+
T cells (Figure 2F). These findings indicate that Cbl-b deficiency
in T cells is sufficient for stronger Th2 and Th9 responses in vivo.
As loss of Cbl-b lowers the threshold for T cell activation
(Bachmaier et al., 2000; Chiang et al., 2000; Guo et al., 2012),
one would expect that the heightened Th2 and Th9 responsesell Reports 6, 709–723, February 27, 2014 ª2014 The Authors 711
Figure 2. Cblb/ Mice Are Highly Susceptible to Asthma Induction and Display Heightened Th2 and Th9 Responses
(A) Airway inflammation and mucus production in OVA-sensitized WT and Cblb/ mice as determined by H&E staining (top) and PAS staining (bottom).
Original magnification, 340 (H&E), 3100 (PAS). Semiquantitative analysis of the severity of peribronchial inflammation and the abundance of PAS-positive
mucus-containing cells was performed (n = 5; *p < 0.05, compared with Cblb/ mice).
(B) Inflammatory cells from BAL fluid.
(C) Respiratory system resistance (Rsr) in WT and Cblb/ mice after OVA rechallenge.
(legend continued on next page)
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in Cblb/ mice might result from hyperresponsiveness to anti-
gen stimulation. To test this, we adoptively transferred naive
CD4+ T cells from DO11.10.Rag1/ and DO11.10.Rag1/
Cblb/ mice into WT BALB/c recipients, and then immunized
with OVA at 100 mg/ml in alum, which is the dose used to induce
asthma. We monitored the expression of early T cell activation
markers, including CD25 and CD69, in antigen-specific KJ-1-
26+ cells during T cell activation. Our data show that immuniza-
tion with OVA peptide at a 100 mg/ml in alum did not induce
heightened levels of activation in Cblb/ T cells, as revealed
by the surface expression of the early activation markers CD25
and CD69 (Figure S2). Our data therefore suggest that the
heightened Th2 and Th9 responses and allergic airway inflam-
mation observed in the absence of Cbl-b are not likely due to
hyperresponsiveness of Th2 or Th9 cells to antigen stimulation
in vivo. This is further supported by the fact that comparable
amounts of IFN-g were detected in the BAL fluid of OVA/alum-
immunized WT and Cblb/ mice or BALB/c nude mice that
received naive CD4+ T cells from WT and Cblb/mice (Figures
2D and 2F), because the lower threshold should also lead to
enhanced IFN-g in the BAL fluid.
Cbl-b Selectively Inhibits IL-4/Stat6 Signaling in T Cells
Wenext sought to determine themolecular mechanism bywhich
Cbl-b inhibits Th2 and Th9 cell differentiation. It has been well
documented that signals derived from both the TCR and IL-4R
are required for Th2 or Th9 cell differentiation (Wan and Flavell,
2009; Kaplan, 2013). It has been shown that Cbl-b does not regu-
late TGF-b signaling in T cells (Harada et al., 2010; Qiao et al.,
2013).We previously showed that TCR/CD28-induced activation
of MAPKs, NF-kB, and NF-AT is comparable between WT and
Cblb/ T cells (Qiao et al., 2008), suggesting that the potentia-
tion of Th2 and Th9 cell differentiation in the absence of Cbl-b
may be due to augmented expression of IL-4R or aberrant acti-
vation of IL-4R signaling. The expression of IL-4Ra was compa-
rable between WT and Cblb/ CD4+ T cells (data not shown),
suggesting that the heightened Th2 and Th9 cell differentiation
in Cblb/ T cells does not result from increased IL-4Ra
expression.
Triggering of IL-4R by IL-4 induces activation of JAKs/Stat6
signaling and is essential for initiation of both Th2 and Th9 cell
differentiation (Kaplan et al., 1996; Kaplan, 2013). We therefore
assessed the phosphorylation of JAKs/Stat6 in response to IL-
4 in WT and Cblb/ CD4+ T cells. Although JAK-1 and JAK-3
phosphorylation was comparable between WT and Cblb/
CD4+ T cells, IL-4-induced Stat6 phosphorylation at Y641 was
much stronger in Cblb/ CD4+ T cells than in WT CD4+
T cells (Figure 3A). To assess the state of Stat6 Y641 phosphor-
ylation during Th2 cell differentiation, we measured Stat6 Y641
phosphorylation. We found that Stat6 Y641 phosphorylation
was induced in both WT and Cblb/ T cells during Th2 cell dif-
ferentiation, and that the loss of Cbl-b led to a greater increase(D) Serum IgE and BAL IFN-g, IL-4, IL-5, IL-9, and IL-13 detected by ELISA (*p <
(E) H&E staining of lungs in BALB/c nudemice (n = 4) that were adoptively transfer
equilibrate 30 days to avoid homeostatic proliferation, and immunized with OVA
(F) IFN-g, IL-4, IL-5, IL-9, and IL-13 concentrations in the BAL fluid and IgE in the se
T cells, detected by ELISA (*p < 0.05 and **p < 0.01, compared with Cblb/ mic
Cof Stat6 Y641 phosphorylation at all time points (Figure 3B).
The kinetics of Stat6 phosphorylation revealed a first peak at
0.5 hr after stimulation, a second peak at day 2, a decline at
day 3, and another increase at days 4 and 5. Our data suggest
that the first peak of Stat6 phosphorylation at Y641 may repre-
sent the direct effect of exogenous IL-4 added in the culture,
whereas the second and third peaks may be due to the endog-
enous secretion of IL-4 in the culture.
Since Stat6 is important for the induction of GATA3 (Murphy
et al., 2000), we measured the nuclear expression of Stat6,
GATA3, and other transcription factors involved in Th2 cell differ-
entiation, and IRF4 from differentiated Th9 cells. We found that
expression of Stat6, GATA3, and IRF4 was increased in Cblb/
CD4+ T cells (Figure 3C). In contrast, the nuclear expression of
T-bet, the master transcription factor for Th1 cell differentiation
(Szabo et al., 2000; Murphy et al., 2000), was comparable
between WT and Cblb/ CD4+ T cells under Th1-biased condi-
tions (Figure 3C), consistent with the comparable Th1 cell differ-
entiation in vitro between WT and Cblb/ T cells, as shown
in Figure 1B. We also did not observe an increase in PU.1 ex-
pression by differentiated Cblb/ Th9 cells (data not shown),
suggesting a more important role for IRF4 in Th9 differentiation
in the absence of Cbl-b.
The binding sites of Stat6 at the Gata3 gene locus and Il9
promoter were recently identified (Onodera et al., 2010; Yang
et al., 2013); therefore, we tested whether the absence of
Cbl-b results in increased binding of Stat6 at the Gata3 and Il9
promoter region by performing Stat6 chromatin immunoprecipi-
tation (ChIP) assays using Gata3 and Il9 as the target genes. We
found markedly augmented Stat6 binding to the gata3 S7 region
in CD4+ T cells lacking Cbl-b at 30 min and 24 hr of stimulation
with TCR/CD28 and IL-4, or increased binding of Stat6 to the
Il9 promoter region in Cblb/ CD4+ T cells at 30 min of stimula-
tion with TCR/CD28, IL-4, and TGF-b (Figure 3D).
To further verify that Cbl-b negatively regulates GATA3 via
Stat6, WT and Cblb/ CD4+ T cells were retrovirally infected
with GATA3 and stimulated with anti-CD3 and anti-CD28 in the
presence of anti-iL-4, which blocks IL-4/Stat6 signaling. Overex-
pression of GATA3 in both WT and Cblb/ T cells bypassed
the IL-4/Stat6 signaling to equally drive Th2 cell differentiation
(Figure 3E), further indicating that Cbl-b suppresses Th2 cell
differentiation upstream of GATA3.
Cbl-b Physically Associates with Stat6 upon IL-4
or TCR/CD28 Stimulation
Having shown that Cbl-b negatively regulates Stat6, we further
investigated the mechanism of this regulation by determining
whether Cbl-b associates with Stat6. Cbl-b was found to specif-
ically associate with Stat6, but not GATA3, c-Maf, or JunB upon
IL-4 and TCR/CD28 stimulation. No association of Stat6 with
c-Cbl was observed (Figure 4A). To confirm this, we performed
glutathione S-transferase (GST) pull-down assays in which0.05 and **p < 0.01, compared with Cblb/ mice).
red (i.v.) with naive CD4+ T cells (53 106) fromWT orCblb/mice, permitted to
as in (A). Original magnification 3100.
rum of OVA-sensitized BALB/c nudemice receiving naiveWT orCblb/CD4+
e). Data represent three independent experiments (mean ± SD).
ell Reports 6, 709–723, February 27, 2014 ª2014 The Authors 713
JunB 
actin 
Gata3 
Stat6 
WT 
Th2 
Th1 
actin 
T-bet 
Cblb-/- 
B 
p-Stat6 (Y641) 
actin 
IL-4 (min): 
Cblb-/- WT 
  0   0 15 15 30 30 
A 
p-JAK-1 
p-JAK-3 
c-Maf 
C 
input 
E 
C
D
4 
GFP 
WT WT 
GFP-RV GFP-RV GATA3-RV GATA3-RV 
Cblb-/- Cblb-/- 
G
FP
 
28 42.6 38.3 30.1 
1.6 2.4 13.2 13.3 
1.0 0.8 
1.0 1.0 
1.0 1.1 
1.0 1.5 
1.0 2.3 
1.0 1.1 1.1 1.0 1.1 1.1 
1.0 1.9 2.0 1. 0 2.2 1.7 
1.0 1.7 1.9 1.1 1.5 1.3 
Irf4 
actin 
Th9 
1.0 0.9 
1.0 2.2 
1.0 1.0 
1.0 0.7 
1.0 1.5 1.6 1.0 3.0 3.0 
D 
W
T 
W
T 
W
T 
Stim.(h): 0 0 0.5 0.5 24 24 
Gata3 S7 
IP: IgG         anti-Stat6 
0 
  1.0  1.0  1.0  1.0   1.2   1.2  1.5    
 1.0  1.3   1.4   1.3  1.3   1.2  1.0  
C
bl
b-
/- 
C
bl
b-
/- 
C
bl
b-
/- 
W
T 
p-Stat6 (Y641) 
R
el
at
iv
e 
C
el
l N
um
be
r 
TCR/CD28/IL-4 (h) 
  0   0.5   2.0   24   48   72   96   120 
W
T
 
C
blb
-/- 
1.9 50.6 
3.6 82.1 
9.5 
21.1 
26.8 60.8 
83.2 
8.7 
29.8 68.1 
48.1 
71.8 69.1 
25 
pS
ta
t6
+  C
el
ls
 (%
) 
Time (h) 
* 
* 
** 
* 
* 
* ** 
Il9 
 1.0   1.0   1.0   1.2  1.3   1.1  1.0  
  1.0   1.0   1.0   1.2   2.2  1.3  1.5    
input 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
WT Cblb-/- 
GFP-RV 
GATA3-RV 
IL-4 
IL
-4
+  C
el
ls
 (%
) 
0 
20 
40 
60 
80 
100 
0 0.5 2 24 48 72 96 120
WT Cblb-/- 
Figure 3. Loss of Cbl-b Results in Heightened Activation of Stat6
(A) Immunoassay of phosphorylation of JAK-1, JAK-3, and Stat6 in CD4+ T cells of WT and Cblb/mice treated with mouse IL-4 (5 ng/ml) at different times. (B)
Flow-cytometric analysis of the phosphorylation of Stat6 at Y641 in WT and Cblb/ CD4+ T cells during Th2 cell differentiation.
(C) Immunoassay of transcription factors (Stat6, GATA3, c-Maf, JunB, IRF4, and T-bet) in nuclear extracts of differentiated Th1, Th2, and Th9 cells from WT and
Cblb/ mice in response to anti-CD3 restimulation for 4 hr. b-actin was used to indicate equal protein loading.
(D) ChIP assay of Stat6 binding to theGata3S7 region or the Il9 promoter region in nuclear extracts of naiveWTandCblb/CD4+ T cells stimulatedwith anti-CD3,
anti-CD28, and IL-4, or anti-CD3, anti-CD28, IL-4, and TGF-b for 0.5 hr and 24 hr. The band intensities were quantified using the Li-Cor Odyssey Imaging System.
(E) Naive CD4+ T cells from WT and Cblb/ mice cultured under Th2 differentiation conditions and retrovirally transfected with two bicistronic retroviruses
expressing GFP-GATA3 or GFP vector. The IL-4-expressing cells were assessed by intracellular staining. Data shown are gated on the GFP+ population. Data are
representative of three independent experiments.
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GST-Stat6 (aa 1–680) or GST was incubated with lysates from
CD4+ T cells that had been stimulated with IL-4, anti-CD3 plus
anti-CD28, or both. As shown in Figure 4B, Cbl-b bound to
GST-Stat6 only upon TCR/CD28 stimulation, and none of the
other E3 ubiquitin ligases tested bound to Stat6. To determine
whether Cbl-b also affects the differentiation of other Th subsets,
we investigated whether Cbl-b could associate with other Stats.
We found that Cbl-b did not bind to Stat1 upon IFN-g stimulation,
to Stat4 upon IL-12 stimulation, or to Stat3 upon IL-6 stimulation
(Figure S3A). Therefore, Cbl-b appears to specifically regulate
Stat6 during Th2 and Th9 cell differentiation.
To assess whether c-Cbl regulates Th2 cell differentiation, we
made use of c-Cbl/ mice (Chiang et al., 2000). Naive CD4+
T cells from WT and c-Cbl/ mice were cultured under the
Th2 cell differentiation conditions. CD4+ T cells lacking c-Cbl
showed no Th2-biased phenotype (Figure S3B). Furthermore,
although c-Cbl/ CD4+ T cells displayed increased phosphory-
lation of Stat5 at 5 min upon IL-2 stimulation, Stat6 phosphoryla-
tion at Y641 was comparable upon IL-4 stimulation in WT and
c-Cbl/ T cells (Figure S3C). These data suggest that c-Cbl
does not inhibit Th2 cell differentiation. As Stat5 has also been
shown to regulate Th2 and Th9 cell differentiation, we assessed
Stat5 phosphorylation in response to IL-2 in naive WT and
Cblb/ CD4+ T cells. Stat5 phosphorylation was not increased
in Cblb/ CD4+ T cells in response to IL-2 (Figure S3D), sug-
gesting that Cbl-b regulates Th2 and Th9 cell responses inde-
pendently of Stat5.
It is possible that Cbl-b interacts with Stat6 via two mecha-
nisms: (1) Cbl-b may bind to Stat6 through its TKB domain
with phosphotyrosine(s) of Stat6 upon IL-4 stimulation; and (2)
phosphotyrosine residues of Cbl-b may bind to the SH2 domain
of Stat6 upon TCR/CD28 stimulation. To investigate the modes
of interaction, we used 293T cells that lack detectable Stat6
but retain other IL-4R signaling components necessary for
Stat6 activation (Mikita et al., 1996). To determine whether IL-
4-induced Cbl-b-Stat6 interaction is mediated by Cbl-b’s TKB
domain, we transfected 293T cells with hemagglutinin (HA)-
tagged Cbl-b or Cbl-b N1/3 (TKB only), or Cbl-b C2/3 (without
TKB) mutants (Figure 4C) together with Flag-tagged Stat6, and
stimulated them with IL-4. We found that Cbl-b and Cbl-b N1/
3, but not Cbl-b C2/3, bound to Stat-6, suggesting that IL-4-
induced Cbl-b-Stat-6 association requires the Cbl-b TKB
domain (Figure 4D). To define whether TCR/CD28-mediated
Cbl-b-Stat-6 association is mediated by the interaction of tyro-
sine-phosphorylated Cbl-b and the Stat6 SH2 domain, we
generated GST-Stat6 SH2 recombinant proteins (Figure 4E)
and performed a GST pull-down assay. As shown in Figure 4F,
GST-Stat6 (aa 1–680) and GST-Stat6 SH2, but not GST-Stat6
TAD, bound to Cbl-b in CD4+ T cells stimulated with TCR/
CD28, supporting the notion that the Stat6 SH2 domain interacts
with tyrosine residues of Cbl-b. Thus, Cbl-b’s interaction with
Stat6 can occur via either its TKB domain or phosphotyrosine
residues.
To test whether IL-4-induced Cbl-b-Stat6 interaction inter-
feres with TCR/CD28-induced Cbl-b-Stat6 association, we per-
formed a competition assay using a phosphopeptide derived
from IL-4R, which binds to the SH2 domain of Stat6 (Hou
et al., 1994; Mikita et al., 1998). The phosphopeptide abrogatedCboth IL-4- and TCR/CD28-induced Cbl-b-Stat6 interaction (Fig-
ure S4) because binding of the peptide to the SH2 domain of
Stat6 blocks its interaction with the IL-4R. This in turn prevents
Stat6 tyrosine phosphorylation, leading to the inability of Stat6
to bind to Cbl-b’s TKB domain and phosphotyrosine residues.
In support of this, comparable binding levels of Cbl-b to Stat6
were observed in T cells stimulated with TCR/CD28 or TCR/
CD28/IL-4, suggesting that IL-4-induced Cbl-b-Stat6 associa-
tion does not interfere with the interaction between Cbl-b and
Stat6 induced by TCR/CD28 (Figures 4A and 4B). Furthermore,
Cbl-b interacted with Stat6 in the cytosol, but not in the nuclei,
as revealed by coimmunoprecipitation (Figure 4G).
Stat6 Phosphorylation at Y641 Is Required for Its
Ubiquitination
The phosphorylation of Stat6 at Y641 is a critical step for its cat-
alytic activity (Mikita et al., 1998). To determine the relationship
between Stat6 Y641 phosphorylation and Stat6 ubiquitination,
we first examined the kinetics of Stat6 Y641 phosphorylation
and ubiquitination, and Cbl-b degradation. Stat6 Y641 phos-
phorylation and ubiquitination both occurred at 1 min of ligation
through CD3/CD28 and IL-4, but Stat6 phosphorylation peaked
at 5–15 min and then declined (Figure S5A, top). In contrast,
Stat6 ubiquitination peaked at 30–60 min after stimulation. Cbl-
b degradation occurred at 15 min and was maintained at lower
levels at 60 min of TCR/CD28/IL-4 stimulation (Figure S5A, bot-
tom). These data suggest that Stat6 phosphorylation at Y641
may be required for Stat6 ubiquitination and degradation. This
was verified with the Stat6 Y641 mutant (Y641W), which abro-
gated ubiquitination induced by IL-4 (Figure S5B). Collectively,
these data strongly indicate that phosphorylation at Y641 is
required for Stat6 ubiquitination.
Cbl-b Is the E3 Ubiquitin Ligase for Stat6
To identify whether Cbl-b acts as an E3 ubiquitin ligase for Stat6,
we coexpressed HA-tagged Cbl-b or Cbl-b C373A mutant, in
which the active-site cysteine at position 373 is substituted
with alanine (Ettenberg et al., 2001), with His-tagged ubiquitin
and Flag-tagged Stat6 in 293T cells, and stimulated transfected
cells with IL-4. Cotransfection with HA-taggedCbl-b, His-tagged
ubiquitin, and Flag-tagged Stat6 resulted in Stat6 ubiquitination,
whereas ubiquitination was abrogated with HA-tagged Cbl-b
C373A (Figure 5A). To confirm this, CD4+ T cells from Cblb/
mice and their WT littermates were pretreated with MG-132
and stimulated with IL-4 in the presence or absence of anti-
CD3 and anti-CD28. Cbl-b deficiency impaired IL-4R- or TCR/
CD28/IL-4R-induced Stat6 ubiquitination (Figure 5B, top). In
further support of this observation, CD4+ T cells isolated from
mice expressing the Cbl-b RF C373A mutation (Oksvold et al.,
2008) resulted in abrogation of Stat6 ubiquitination (Figure 5B,
bottom). Further analysis showed that IL-4-induced Stat6 degra-
dation was exacerbated in TCR/CD28 signaling, and this was
completely inhibited by Cbl-b deficiency or the proteasome in-
hibitor MG-132 (Figure 5C). The key role of IL-4R signaling was
further demonstrated by the observation that TCR/CD28 stimu-
lation alone did not induce Stat6 degradation (Figure 5D). To
determine whether Cbl-b ubiquitin ligase activity is critical for
Th2 development, we performed a Th2 cell differentiation assayell Reports 6, 709–723, February 27, 2014 ª2014 The Authors 715
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Figure 4. Stat6 Specifically Associates with Cbl-b upon IL-4 or TCR/CD28 Stimulation
(A) Immunoprecipitation (IP) of proteins from CD4+ T cells purified from BALB/c mice treated with mouse IL-4 (5 ng/ml), anti-CD3 plus anti-CD28, or both for
15 min with anti-Stat6, anti-GATA-3, anti-c-Maf, and anti-JunB, respectively, and blotted with anti-Cbl-b or anti-c-Cbl.
(B) Affinity precipitation of lysates from CD4+ T cells stimulated with IL-4 or anti-CD3 plus anti-CD28, or both with GST or GST-Stat6 (aa 1–680), captured by
glutathione sepharose beads, and analyzed by immunoblot analysis with antibodies against Cbl-b, Itch, TRAF-2, TRAF-6, c-Cbl, and Nedd4. The expression of
GST fusion protein was confirmed by anti-GST immunoblotting.
(C) Schematic design of Cbl-b mutants.
(D) Top: IP of proteins from lysates of 293T cells transiently transfected with Flag-tagged Stat6 and HA-tagged Cbl-b, or Cbl-b N1/3 or Cbl-b C2/3 mutants and
treated with IL-4 with anti-HA, followed by immunoblot analysis with anti-Flag. Middle and bottom: immunoblot analysis of whole-cell lysates with anti-HA and
anti-Flag.
(E) Schematic design of Stat6 mutants.
(legend continued on next page)
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using CD4+ T cells from the Cbl-b C373A mutant mice. As
expected, the Cbl-b C373A mutation resulted in heightened
Th2 cell development in vitro (Figure 5E). Collectively, our data
establish Cbl-b as a key E3 ubiquitin ligase for regulating Stat6.
Lysines 108 and 398 Are the Ubiquitination Sites
of Stat6
To determine the lysine residue(s) responsible for Stat6 ubiqui-
tination, we first used the Bayesian Discriminant Method
(BDM-PUB; http://bdmpub.biocuckoo.org/) to predict potential
ubiquitination sites. We identified 22 potential lysine residues
within Stat6, and chose the 14 residues with scores higher
than 1.0 (K108, K194, K199, K252, K307, K361, K367, K369,
K374, K374, K398, K618, K621, and K647; Figure S6A). To deter-
mine the Stat6 ubiquitination site(s), we made point mutations
(K to R) at each lysine. Only mutations at K108 and K398 signif-
icantly diminished Stat6 ubiquitination in 293T cells induced by
IL-4 stimulation (Figures 6A and S6B), indicating that K108 and
K398 are the ubiquitination sites. To define the biological rele-
vance of K108 and K398, we generated Stat6 mutants carrying
K108R, K398R, or both, and reconstituted Stat6/ CD4+
T cells with WT Stat6 or Stat6 K108R, K398R, or both. We found
that more Stat6/ CD4+ T cells reconstituted with Stat6 K108R,
K398R, or K108R/K398R differentiated into Th2 cells compared
with those reconstituted with WT Stat6 (Figure 6B). Consistent
with this observation, stimulation of Stat6/ CD4+ T cells
reconstituted with WT Stat6 with TCR/CD28/IL-4 induced
Stat6 degradation, but Stat6 degradation was significantly
reduced or abrogated in Stat6/ CD4+ T cells reconstituted
with Stat6 K108R, K398R, or K108R/K398R (Figure 6C). These
findings clearly identify the Stat6 ubiquitination sites and verify
the importance of Stat6 ubiquitination in the regulation of Th2
cell differentiation.
Introducing Stat6 Deficiency Abrogates Hyper-Th2
Responses but Only Partially Attenuates Th9 Responses
in Cblb/ Mice
To further elucidate the role of Stat6 in hyper-Th2 and Th9 re-
sponses in Cblb/ mice, we introduced Stat6 deficiency into
Cblb/ mice. If the heightened Th2 and Th9 responses caused
by Cbl-b deficiency are mediated by Stat6, one would predict
that loss of Stat6 should abrogate these hyperresponses in
Cblb/ mice. As predicted, the heightened Th2 cell differentia-
tion in vitro in the absence of Cbl-bwas abrogated by introducing
Stat6 deficiency (Figure 7A). Unexpectedly, loss of Stat6 only
moderately affected Th9 cell differentiation by Cblb/ CD4+
T cells (Figure 7B). To further confirm whether Stat6 deficiency
attenuates aberrant airway inflammation and Th2 and Th9 re-
sponses in vivo, we immunized WT, Cblb/, Stat6/, and
Cblb/Stat6/mice with OVA in alum. Stat6 deficiency greatly
diminished heightened airway inflammation and PAS+ airway cell(F) Affinity precipitation of proteins from lysates of BALB/c CD4+ T cells stimulate
GST-Stat6 SH2 mutant, captured by glutathione sepharose beads, and analyze
lysates with anti-Cbl-b was used as a loading control.
(G) Top: IP of cytosolic and nuclear extracts of naiveWTCD4+ T cells stimulated w
and blotted with anti-Cbl-b and anti-Stat6, respectively. Bottom: Immunoblot an
cytoplasmic protein), and anti-YY1 (for detection of nuclear protein), respectively
Caccumulation (Figure 7C), and inhibited total serum IgE titers,
eosinophil infiltration, and Th2 cytokines (IL-4, IL-5, and IL-13)
in the BAL of Cblb/ mice (Figure 7D). In contrast, Stat6
deficiency only moderately attenuated IL-9 levels in the BAL
of Cblb/ mice (Figure 7D). These data are consistent with
the fact that airway inflammation was completely diminished
in Stat6/ mice, whereas some residual airway inflammation
was observed in Cblb/Stat6/ mice (Figure 7C). To further
confirm whether the residual airway inflammation in Cblb/
Stat6/ mice was due to Th9 responses, we treated
Cblb/Stat6/ mice with a neutralizing anti-iL-9 antibody. As
expected, anti-iL-9 treatment completely abrogated residual
airway inflammation in Cblb/Stat6/ mice (Figure 7C).
Stat6 has been shown to be required in airway epithelial and
smooth muscle cells in addition to Th2 and Th9 cells (Matsukura
et al., 2001; Perkins et al., 2011). To further verify that Stat6 is the
downstream target of Cbl-b in T cells, we performed adoptive
transfer of naive CD4+ T cells from WT, Cblb/, Stat6/, and
Cblb/Stat6/ mice into BALB/c nude mice, followed by
immunization with OVA in alum and challenge with an aerosol
form of OVA. Consistent with the data shown in Figures 2E and
2F, BALB/c nude mice that received Cblb/ CD4+ T cells
developed severe airway inflammation upon immunization and
airway challenge with OVA, and this heightened airway inflam-
mation was significantly reduced, but not abrogated, when
Stat6 deficiency was introduced (Figure S7). Taken together,
our data demonstrate that Stat6 is the target for Cbl-b during
Th2 cell differentiation both in vitro and in vivo. Our data also sug-
gest that Th9 cell differentiation regulated by Cbl-b is mediated
by both Stat6-dependent and -independent mechanisms.
DISCUSSION
Cblb/ mice are highly susceptible to autoimmunity (Chiang
et al., 2000; Jeon et al., 2004), which is believed to be mediated
by Th17 (Bettelli et al., 2007; Korn et al., 2009). Therefore, it is
possible that Cbl-b may also regulate Th17 cell differentiation.
However, our in vitro studies suggest that loss of Cbl-b does
not affect Th17 cell differentiation, which contradicts a recent
report in which IL-17 production, but not IL-17 intracellular stain-
ing, was used as a readout for Th17 cells (Gruber et al., 2009). It is
possible that Cbl-b deficiency in other cell types, such as B cells
and monocytes/macrophages, may affect in vivo Th17 re-
sponses. Indeed, Cbl-b deficiency results in hyperactivation of
B cells via BCR (Sohn et al., 2003) or CD40 (Qiao et al., 2007),
and monocytes via TLR-4 (Bachmaier et al., 2007). The height-
ened production of proinflammatory cytokines via B cells
and/or monocytes/macrophages in the absence of Cbl-b may
eventually affect Th17 responses in vivo. In keeping with this
scenario, we have found that Cblb/ mice are highly suscepti-
ble to experimental autoimmunemyocarditis (EAM), but it seemsd with or without anti-CD3 and anti-CD28 with GST-Stat6, GST-Stat6 TAD, or
d by immunoblot analysis with anti-Cbl-b. Immunoblot analysis of whole-cell
ith anti-CD3, anti-CD28, and IL-4 for 0, 5, 15, 30, 60, and 90min with anti-Stat6,
alysis of the cytosolic and nuclear extracts with anti-G6DPH (for detection of
. Data represent one of three independent experiments.
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Figure 5. Cbl-b Is the E3 Ubiquitin Ligase for Stat6
(A) IP of proteins from lysates of 293T cells transiently transfected with plasmids encoding with Flag-tagged Stat6, HA-tagged Cbl-b, or Cbl-b C373Amutant, and
His-tagged ubiquitin with anti-Flag, followed by immunoblot analysis (IB) with anti-Flag and anti-HA, respectively.
(B) IP of proteins from CD4+ T cells from WT and Cblb/mice (top) or WT and CblbC373A mice (bottom) pretreated with MG-132 for 30 min, and stimulated with
IL-4 in the presence or absence of anti-CD3 and anti-CD28 with anti-Stat6, followed by immunoblotting with anti-ubiquitin and reblotting with anti-Stat6.
(C) Top: immunoblot analysis of total protein levels of Stat6 of WT and Cblb/ CD4+ T cells stimulated for 1, 2, and 4 hr with IL-4 in the presence or absence of
anti-CD3 plus anti-CD28. Bottom: immunoblot analysis of Stat6 protein expression ofWTCD4+ T cells treated with anti-CD3, anti-CD28, and IL-4 for 1, 2, and 4 hr
with or without MG-132. Actin was used as a loading control.
(D) Immunoblot analysis of Stat6 protein expression of WT and Cblb/ CD4+ T cells stimulated with anti-CD3 and anti-CD28 for 15, 30, 60, and 120 min.
(E) Intracellular staining of Th2 cells differentiated in vitro from purified naive CD4+CD25CD62LhiCD44lo T cells of WT or CblbC373A mice. Numbers in the
quadrants indicate the percentage of IL-4/IFN-g-producing cells in the CD4+ population. Results are representative of three independent experiments.that the heightened Th17 responses in EAM observed inCblb/
mice are not due to T cell-intrinsic loss of Cbl-b (our unpublished
data). Nevertheless, the reconstitution of BALB/c nudemice with
Cblb/ CD4+ T cells leads to severe airway inflammation upon718 Cell Reports 6, 709–723, February 27, 2014 ª2014 The AuthorsOVA immunization and challenge associated with heightened
Th2 and Th9 responses (Figure 2F), indicating a T cell-intrinsic
role for Cbl-b in the regulation of Th2 and Th9 cell differentiation.
In support of this, in vitro Th differentiation assays using naive
Figure 6. K108 and K398 Are Stat6 Ubiquitination Sites
(A) IP of lysates of 293T cells transfected with Flag-tagged Stat6, Stat6 K108R, or Stat6 K398R together with HA-tagged Cbl-b and His-tagged ubiquitin with
anti-Flag, and followed by immunoblotting with anti-His. The lysates were blotted with anti-Flag, anti-HA, and anti-actin.
(B) Intracellular staining of Stat6/ CD4+ T cells reconstituted with Stat6 or Stat6 K108R, K398R, or both, or an empty vector by lentiviral infection, and
differentiated under Th2-polarizing condition with anti-iL-4. Numbers in the quadrants indicate the percentage of GFP+IL-4-producing cells in the CD4+
population.
(C) Immunoblotting analysis of lysates of Stat6/ CD4+ T cells lentivirally reconstituted with Stat6 or Stat6 K108R, Stat6 K398R, or both, and stimulated with
anti-CD3, anti-CD28, and IL-4 for 2 hr. Results are representative of two independent experiments.CD4+ T cells showed an aberrant differentiation of Cblb/
T cells into the Th2 and Th9 cell lineage (Figures 1B–1D). There-
fore, our data collectively indicate that Cbl-b specifically inhibits
Th2 and Th9 cell differentiation, providing a potential pharma-
ceutical target for allergic asthma. Our data differ from that re-
ported by Oh et al. (2011), who failed to observe heightened
airway inflammation and Th2 and Th9 responses in Cblb/
mice upon OVA/alum immunization protocol. The increased
airway inflammation they observed in Cblb/ mice upon intra-
nasal challenge was predominantly mediated by a Th1 response
in the lung. This discrepancy may be due to the different genetic
backgrounds of the mice (B6 versus BALB/c) and/or the doses
of OVA used.
Recent studies indicate that Stat6 appears to be required
for Th9 cell differentiation (Goswami et al., 2012; Kaplan,C2013). Surprisingly, although we observed a significant increase
in Th9 cell responses in vitro and in vivo in the absence of Cbl-b
(Figures 1 and 2), Stat6 deficiency only partially reduced this Th9
response in vitro and in vivo (Figures 7 and S7). This is supported
by evidence that some residual airway inflammation was still
present in Cblb/Stat6/ mice (Figures 7 and S7). Therefore,
Cbl-b, through targeting Stat6 for ubiquitination, inhibits Th2
responses, but Cbl-b inhibits Th9 responses via both Stat6-
dependent and -independent mechanisms.
We found that Stat6 specifically binds Cbl-b upon IL-4 stimu-
lation, and that TCR/CD28 stimulation strengthens this interac-
tion. It seems that Cbl-b interacts with Stat6 via two different
mechanisms depending upon the stimuli. IL-4-induced Cbl-b-
Stat6 association requires the Cbl-b TKB domain, which
potentially interacts with tyrosine residues of Stat6, whereasell Reports 6, 709–723, February 27, 2014 ª2014 The Authors 719
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TCR/CD28-induced Cbl-b-Stat6 interactionmay bemediated by
phosphorylated Cbl-b C-terminal tyrosine residues and the SH2
domain of Stat6. In keeping with these observations, we found
that Stat6 undergoes proteasomal modification upon IL-4 treat-
ment, which is heightened by TCR/CD28 stimulation, whereas
this process is abrogated in the absence of Cbl-b (Figure 5C).
Although it is unknown why TCR/CD28 stimulation does not
induce Stat6 ubiquitination but induces a strong interaction
between Cbl-b and Stat6, it is possible that the orientation of
this interaction is unable to promote the transfer of ubiquitin,
whereas the binding of the Cbl-b TKB domain to phosphotyro-
sine residues of Stat6 upon IL-4 stimulation provides a correctly
aligned interaction that can allow Stat6 ubiquitination.
Our data demonstrate that Stat6 is ubiquitinated at K108 and
K398 by Cbl-b, and that Stat6 ubiquitination is a critical post-
translational regulatory mechanism for Stat6. Although it was
previously reported that Stat6 may be modified by calcium-
dependent proteases via a proteolytic mechanism (Zamorano
et al., 2005), it remained unknown whether Stat6 is regulated
via the ubiquitin-proteasome pathway during Th2 and Th9 cell
differentiation. Our study demonstrates that Stat6 is regulated
by the ubiquitination-proteasome pathway, and to identify
Cbl-b as the E3 ubiquitin ligase that targets Stat6. Therefore,
we have identified a mechanism for Cbl-b in regulating Th2
and Th9 cell differentiation that may serve as an important
therapeutic target for allergic diseases, including asthma.
EXPERIMENTAL PROCEDURES
Mice
Details regarding the mice used in this study are provided in the Supplemental
Experimental Procedures. All experimental protocols followed NIH guidelines
and were approved by the institutional animal care and use committees of
the University of Chicago and Ohio State University. All of the mice were
6–10 weeks old when they were used for experiments.
In Vitro Th1, Th2, Th9, and Th17 Differentiation Assays
Naive CD4+ T cells isolated from WT and Cblb/ mice were stimulated with
plate-bound anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) in the presence
of Th1, Th2, Th17, or Th9 cytokine cocktails as previously described (Ying
et al., 2010; Chang et al., 2010). Details are provided in the Supplemental
Experimental Procedures.
Immunoprecipitation and Western Blotting
The conditions for immunoprecipitation and immunoblotting were described
previously (Zhang et al., 2002; Li et al., 2004; Qiao et al., 2008). Details are
provided in the Supplemental Experimental Procedures.
Asthma Induction
Mice (five mice/group) were immunized by intraperitoneal (i.p.) injection of
OVA (100 mg/ml; Sigma-Aldrich) adsorbed to 2 mg of an aqueous solution
of aluminum hydroxide and magnesium hydroxide (Alum; Fischer Scientific)Figure 7. Loss of Stat6 Abrogates Hyper-Th2 and Th9 Responses in C
(A and B) Intracellular staining of Th2 and Th9 cells differentiated in vitro from pu
Cblb/Stat6/mice. Numbers in the quadrants indicate the percentage of IL-4/I
(C) H&E and PAS staining of the lungs of WT, Cblb/, Stat6/, and Cblb/S
(*p < 0.05 and **p < 0.01, compared with Cblb/ mice; Mann-Whitney test).
(D) ELISA of IFN-g, IL-4, IL-5, IL-9, and IL-13 concentrations in the BAL fluid and I
mice treated or untreated with anti-iL-9.
Data represent three independent experiments (mean ± SD).
Con day 0 and day 14. After 21 days, challenge doses of OVA were given
through the airways. Details are provided in the Supplemental Experimental
Procedures.
Statistical Analysis
A two-tailed Student’s t test was applied for statistical comparison of two
groups or, when appropriate, two-way ANOVA followed by Bonferroni’s post
hoc test for multiple comparisons and a Mann-Whitney test for nonparametric
data (asthma scoring). A p value of 0.05 or less was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.01.012.
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